dr. mesa on challenges with jak inhibitors in myelofibrosis
Published 4 years ago • 82 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
1:54
dr. mesa discusses jak inhibitors for myelofibrosis
-
1:08
dr. mesa on unanswered questions regarding jak inhibitors in myelofibrosis
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
1:42
dr. mesa on jak inhibitors in the pipeline for myelofibrosis
-
2:22
dr. mesa on the evolving role of jak2 inhibitors in myelofibrosis
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:47
dr. oh on the development of jak inhibitors in myelofibrosis
-
1:05
dr. mesa on rechallenging with jak inhibitor therapy in mpns
-
25:13
update on jak inhibitors for myelofibrosis: there is more than one
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:34:09
jak inhibitors in myelofibrosis: expert insights on cases in personalizing therapy
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
3:48
jak inhibition for the early treatment of myelofibrosis
-
1:01
dr. masarova on the safety of jak inhibitor/targeted therapy combos in myelofibrosis
-
1:26
mesa advises community oncologists on jak inhibitors for intermediate-risk myelofibrosis
-
1:10
dr. ruben mesa on comfort-1 for myelofibrosis
-
2:43
dr. tefferi on the outlook for jak inhibitors in myelofibrosis